Exclusive Interview: Dr. William A. Carter, CEO. Hemispherx Biopharma, Inc. (AMEX:HEB) Print E-mail
By M.E.Garza   
Friday, 12 June 2009 20:48

Dr.William A. Carter, the CEO of Hemispherx Biopharma shares his thoughts on the .add_link li{ float: left; } FDA delay, the flu pandemic and load.

TRT: Approximately 45 Minutes






BiomedReports is not paid or compensated by newswires to

humspm.com

128183000:2016-05-01 00:58:57 disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and .right_top{width:1020px; margin:0 auto; background-color:#000;} investor relation services from various entities and .add_link{padding:8px 0 6px 12px; margin-top: 12px; border: 1px solid #222;} firms. Full disclosures should be read in the 'About Us Section'.


Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter

BioMedReports Q BioMed's CEO featured in article he wrote titled Accelerators Enter When VCs Fear To Tread: https://t.co/NuOXexgSaY $QBIO
BioMedReports DiaMedica Completes Issue of border: 1px solid #303030; Shares for Debt to BFC Group: https://t.co/PbNeO3NBAF $DMCAF
BioMedReports AstraZeneca Beefs Up Immuno-Oncology Pipeline with TapImmune Technology: https://t.co/zvvP1grhgr $TPIV
BMR:1